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Abstract 
Background: Inflammatory and nutritional indexes are prognostic factors in non-small cell lung cancer 
(NSCLC). Furthermore, a low grade of chronic inflammation has been described in the older population 
(inflammaging). We aimed to evaluate the neutrophil-to-lymphocyte ratio (NLR), the Prognostic 
Nutritional Index (PNI), the advanced lung cancer inflammation index (ALI), the platelet-to-lymphocyte 
ratio (PLR), and the Glasgow Prognostic Score (GPS) in young and older patients diagnosed with locally 
advanced NSCLC to determine if significant differences between these groups exist. 
Methods: We conducted a retrospective study analyzing the impact of age on the NLR, PNI, ALI, PLR, and 
GPS among patients diagnosed with stage III NSCLC at Hospital Universitario Doctor Peset between 2010 
and 2015. 
Results: We included 124 patients (84 young, 40 older patients). The median hemoglobin level and 
leukocyte count were lower in the older patients (p = 0.0158 and p = 0.001, respectively). A higher median 
C-reactive protein level was also found in this group (p = 0.0095). Regarding specific inflammatory
indexes, the PNI, comprising inflammatory and nutritional parameters, was lower among the older
patients (p = 0.0463). The median NLR, ALI, and PLR were similar in both age groups. Moreover, no
differences between the age groups were found in the percentage of patients showing high versus low
NLR (cutoff point, 5) or ALI (cutoff point, 18) or in the different GPS groups.
Conclusions: The baseline PNI, hemoglobin level, and lymphocyte count were lower among the older 
patients; furthermore, CRP was higher, possibly, because of a more prominent inflammatory status in 
older patients with lung cancer. No other immunological or nutritional analytical variables were different 
between the age groups. 
Introductionintroduction 
Lung cancer is one of the tumors with the highest mortality, accounting for more than 1.5 million 
deaths in 2012 [1]. Non-small cell lung cancer (NSCLC) is responsible for 85% of all cases [2]. In spite 
of all the progress in prevention and treatment, its prognosis is still poor, and overall survival is 15% 
5 years after the diagnosis. 
Stage III NSCLC occurs in a heterogeneous group of patients, leading to higher complexity in the 
choice of treatment due to differences in characteristics between populations included in clinical 
trials and patients seen in clinical practice. These variations are even greater if we consider older 
patients. According to the results of the study by Molina et al. [2], the median age at diagnosis of 
NSCLC is 70 years in Western countries; however, older populations are underrepresented in clinical 
trials, mainly because of their comorbidities [3, 4]. 
It is known that outcomes for patients diagnosed with cancer are determined not only by tumor 
characteristics but also by patient-related factors. During the last decade, the systemic inflammatory 
response has been demonstrated to play an important role in lung cancer development and 
progression [5]⁠. Furthermore, the connection between cancer prognosis and nutritional factors has 
been studied during the last years [6]. Cachexia is commonly defined as involuntary weight loss 
secondary to an increased catabolism linked to inflammation [7]. The incidence of cachexia among 
patients diagnosed with NSCLC ranges from 18 to 28%. Moreover, precachexia is even more difficult 
to determine, because it is not always identified with the nutritional parameters usually employed. 
Van der Meij et al. [6] found precachexia in 23% of cases, and there is a growing interest in its early 
detection, because it is more effective to make an intervention to revert this process. For all these 
reasons, oncologists are concerned about the factors influencing lung cancer development, the 
potential response to treatment, and the prediction of possible toxicities – especially in older 
patients, a more vulnerable population. Therefore, determining prognostic biomarkers is important 
in this type of tumor. 
Several nutritional and inflammatory indexes have been studied as prognostic factors in stage IV 
NSCLC [8]: the neutrophil-to-lymphocyte ratio (NLR) [9–11], the Prognostic Nutritional Index (PNI) 
[12], the advanced lung cancer inflammation index (ALI) [13], the platelet-to-lymphocyte ratio (PLR) 
[14], and the Glasgow Prognostic Score (GPS) [8, 15, 16]. However, there is only scarce information 
about them with regard to stage III lung cancer, and it is unknown if there are differences in these 
parameters between young and older populations. Nevertheless, previous studies have reported a 
state of low-grade chronic inflammation seen in older individuals, named inflammaging [17]. That is 
why the aim of our study was to investigate if such differences between younger and older 
individuals exist among stage III NSCLC patients. 
Subjects and Methodsmaterials|methods 
Study Design 
We performed an observational retrospective study, including patients diagnosed with locally 
advanced NSCLC (stage III) at Hospital Universitario Doctor Peset between 2010 and 2015. The 
patients were classified according to the guidelines of the Tumor-Node-Metastasis (TNM) staging 
system of the Union for International Cancer Control (7th edition) [18]. Patients older than 18 years 
with a histopathological diagnosis of NSCLC stage III were included, unless their clinical or laboratory 
data were not available. Patients were also excluded if they had been diagnosed with another tumor 
during the previous 3 months, or if an infection or acute complication was found at the moment of 
blood test acquisition, because this could have interfered with our results. 
The clinicopathologic characteristics, comorbidities, and laboratory data (including neutrophil, 
lymphocyte, and platelet counts, as well as C-reactive protein [CRP], albumin, lactate 
dehydrogenase, and hemoglobin levels) were recorded before the patients received any treatment, 
and the data were archived in the hospital’s informatics system. Functional status was assessed 
using the Eastern Cooperative Oncology Group (ECOG) scale, ranging from 0 to 5. 
Inflammation-Based Rates and Scales 
The NLR is defined as the absolute neutrophil count divided by the absolute lymphocyte count 
[19]. The PNI is an inflammatory and nutritional index, calculated with the formula 10 × albumin 
level (g/dL) + 0.0005 × lymphocyte count [9]. The ALI also evaluates the level of systemic 
inflammation, and it is the result of the operation body mass index (BMI) × albumin level (g/dL)/NLR; 
an ALI ≥18 indicates a low grade of inflammation and an ALI <18 a high grade of inflammation in the 
advanced setting [13]. The PLR is determined by the platelet count divided by the lymphocyte count. 
Finally, the GPS combines an inflammatory parameter (CRP) and a nutritional factor (albumin): 
patients are assigned 1 point if they have a CRP level >10 mg/L or hypoalbuminemia (<3.5 g/dL), and 
they are finally classified into groups with 0, 1, or 2 points [20]. 
Statistical Analysis 
The patients were classified into two groups depending on their age, with the cutoff point set at 
70 years. Their demographic and tumor characteristics are reported with descriptive statistics. 
Comparisons between the age groups for categorical variables were performed using the χ2 
independence test or Fisher’s exact test. Continuous variables were compared between the two 
groups using t tests, or the Wilcoxon rank-sum test if data were nonnormally distributed. p < 0.05 
was considered statistically significant in all analyses. 
Also, cutoff points for the NLR and ALI described in previous studies were used to categorize 
these variables into low/high NLR or ALI, in order to perform a comparison between their 
percentages among young and older patients using Fisher’s exact test. For the PLR and PNI, no cutoff 




A total of 124 patients with adequate medical information were analyzed. The demographic and 
tumor characteristics of the two groups are shown in Table 1. The patients ranged in age from 39 to 
82 years (median age, 65.6). In both groups, most patients were male (79.8% in the young group and 
90% in the older group) and had a current or former history of smoking habit. The predominant 
histology was squamous cell carcinoma in both groups (59.5 and 55% in the young and the older 
group, respectively). Also, more than half of the patients were diagnosed with stage IIIB NSCLC (52.4 
and 57.5%, respectively). No statistically significant differences in demographic characteristics were 
found between the two groups. 
BMI and Weight Loss 
The median BMI was significantly lower among the young patients (25.37, vs. 27.91 kg/m2 in the 
older group; p = 0.0095). However, the percentage of patients that had suffered from previous 
weight loss was similar in the two groups (28.5% in the young-adult group and 20% in the older 
patient group; p = 0.3826). 
Blood Count 
Levels of hemoglobin and lymphocytes were significantly lower in older patients (data shown in 
Table 2). Furthermore, the p-value for differences among neutrophil mean counts is shown to be 
close to the significance level (p = 0.0622). 
Inflammation-Based Parameters and Indexes 
The most generic parameter used as a laboratory inflammatory marker in clinical practice is the 
CRP level, which was shown to be statistically significantly higher among our older patients (median 
53.1 mg/L [older] vs. 17.35 mg/L [young]; p = 0.0096). 
Finally, we analyzed the inflammatory indexes in the young adults and older patients, and we 
found that the PNI, which encompasses nutritional and inflammatory information, was significantly 
lower among the patients aged ≥70 years (42.15 in the older patients vs. 45.19 in the young 
patients; p = 0.0463). The comparison is shown in Table 3 and Figure 1. A cutoff value for the PNI has 
not yet been definitively established, although values <45 have been proposed to be related to a 
worse prognosis. 
Fig. 1. Median Prognostic Nutritional Index (PNI) values for young and elderly patients (cutoff 
point, 70 years). 
Nevertheless, no statistically significant differences were observed for the mean values of the 
NLR, PLR, and ALI or the percentage of patients in each GPS risk group (data summarized in Table 3). 
For the NLR, a cutoff point of 5 has consistently been reported to be related to prognosis [19]; thus, 
we dichotomized the variable to investigate if different proportions of patients showed a high NLR in 
the two groups, but this was not observed (as assessed with Fisher’s exact test; p = 1.00). Similarly, 
the ALI was dichotomized using 18 as the cutoff point, and no difference was found (as assessed 
with the χ2 test; p = 0.5616). 
Discussion and Conclusions 
The median age at diagnosis of NSCLC has been rising during the last years, being set in the last 
reports at 70 years [21]. Given the growing percentage of the population older than 65 years in 
Western countries, it may be predicted that the patients that we will treat in our clinical practice will 
probably tend toward an even older population. 
It is widely known that with aging, several progressive changes in physiological systems and 
organs occur [22], as well as presumably in the tumor biology of older patients with cancer. 
Therefore, it is essential that this special subgroup of individuals is studied, and that we weigh 
different factors when we consider the possible therapies that our patients can be offered. Thus, we 
investigated the analytical and clinical parameters of patients diagnosed with stage III NSCLC to 
determine if significant differences exist between younger and older individuals, because this could 
help us in making treatment decisions. 
Regarding demographic characteristics, no statistically significant differences were found 
between the two groups; however, a trend toward a higher percentage of patients with an ECOG 
performance status of 2 was seen in the group of patients aged 70 years or more, which could be 
due to a larger number and greater severity of comorbidities and functional impairment that are 
more frequently seen among older patients [23]. 
Among the clinical nutritional parameters, the BMI was significantly higher among the older 
patients; however, it is important to investigate other nutritional variables, because even obesity 
could still be present in patients suffering from malnutrition, protein deficiency, and also sarcopenia 
[24, 25]. That is why we cannot assume that being overweight sets aside the possibility of nutritional 
impairment. Thus, the BMI may not be an effective screening tool for malnutrition, especially among 
older patients with cancer, since these are often sedentary and typically have a lower muscular 
mass; that is why it was additionally evaluated with laboratory criteria. 
Subsequently, we compared the basic analytical parameters, and we found that the hemoglobin 
level and lymphocyte count were lower in the older patients; furthermore, the older patients had a 
significantly higher median CRP value than the younger patients. This illustrates the divergence in 
bone marrow reserve and hematological function between young adults and older patients and, 
interestingly, is also an indirect sign of inflammatory activity, which has also been reported in 
nononcological older populations [26]. Cancer is also a possible origin of higher CRP levels, but the 
patients in both our groups had the same diagnosis and no significant differences were found in the 
clinical stage of the tumor; therefore, the elevated level of that protein could be attributed to 
functional changes in aging. 
Notwithstanding these data, no differences were observed in other inflammatory variables such 
as the neutrophil count, though a tendency toward having lower neutrophil levels was perceived 
among the older patients. Possibly, cancer could play a role in some of these changes, since 
differences in neutrophil count have not been reported in the general population [27]. Nevertheless, 
it is true that the neutrophil or lymphocyte count individually may have limitations in reflecting the 
inflammation or immune response in patients, which incited the development of indexes that 
comprise more than one of these values to have a better understanding of the inflammatory, 
immunological, and nutritional status of our patients. 
Regarding the specific inflammation-based indexes, the PNI was found to be significantly lower 
among the older patients in our study. This parameter includes nutritional and immunological 
variables and therefore largely reflects the level of systemic inflammation and nutritional status, 
which both play critical roles in disease progression and prognosis in patients diagnosed with cancer 
[28]. Lower PNI values have been associated with worse outcomes in patients diagnosed with 
different types of tumors, including NSCLC, especially in the advanced setting [12, 29], and they have 
also been found to be related to older age and poorer ECOG performance status [30], but mainly in 
Asian populations. However, to our knowledge, only scarce data have been published in our area, 
and even less on localized-stage NSCLC. 
One of the inflammatory indexes that has been widely reported as a prognostic factor in NSCLC 
and a marker for inflammatory response is the NLR [31, 32]; nevertheless, we found no differences 
in median NLR values between the older and the younger patients in our cohort. This could be due 
to a relatively small sample size; nonetheless, although a lower lymphocyte count was observed 
among the older patients in our study, there was also a trend toward a lower neutrophil count. That 
is why another possible explanation is that the high heterogeneity observed in older populations – 
since it is known that older patients differ substantially in their comorbidities, as well as in their 
cognitive, emotional, social, and functional status [33] – may not only influence laboratory 
parameters but also cancer outcomes and the toxicity of treatments. 
The other indexes that we investigated (ALI, PLR, and GPS) were also similar in the two age 
groups. Although older patients are more prone to have poor nutritional and immunological 
conditions [27], cancer itself could also be related to systemic inflammation and impaired nutritional 
function. However, our findings could suggest that changes in the lymphocyte subpopulation and in 
albumin levels (and, therefore, in the indexes that are mainly based on these values) are more 
related to aging than neutrophil and platelet counts (and, subsequently, the ratios based on these 
parameters). 
On the one hand, we would like to mention the limitations of this study, which include – besides 
the relatively small sample size – firstly, its retrospective nature, which was the origin of missing 
parameters for some of the variables, and, secondly, its basis on a single-center experience. 
However, interesting results could still be gained from our cohort, which should be confirmed in 
larger and multicenter series. On the other hand, we would like to outline the strengths of our 
research. Most of the immunological parameters in stage III NSCLC have been studied in Asian 
populations; however, differences between Western and Eastern populations have been reported 
for several diseases, so information regarding this issue needed the assessment that we have 
performed. Moreover, investigations regarding differences between young and older patients 
diagnosed with lung cancer using laboratory parameters provide useful information based on 
reproducible and inexpensive explorations. 
Taking all this together, we found that the nutritional and immunological status of older patients 
diagnosed with stage III NSCLC appears to be different from that of younger patients with the same 
diagnosis – particularly if inflammatory and nutritional parameters are taken into consideration 
together, as is the case with the PNI. As nutritional and immunological parameters have been 
associated with prognosis and outcome in patients diagnosed with lung cancer, our findings have 
clinical implications. Furthermore, the heterogeneity in the aging process makes it even more 
significant to assess clinical and laboratory parameters in a more exhaustive manner, including a 
comprehensive geriatric evaluation. 
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Table 1. Demographics and clinical characteristics of the young (<70 years) and older (≥70 years) 
patients 
<!--Col Count:3--> <70 years (n = 84) ≥70 years (n = 40) 
Age, years 
Median (range) 65.5 (39–82) 
Sex, n (%) 
Male 67 (79.8) 36 (90.0) 
Female 17 (20.2) 4 (10.0) 
<!--Col Count:3--> <70 years (n = 84) ≥70 years (n = 40) 
Smoking status, n (%) 
Nonsmoker 2 (2.4) 5 (12.5) 
Ex-smoker 30 (35.7) 22 (55.0) 
Current smoker 52 (61.9) 13 (32.5) 
ECOG performance status, n (%) 
0 15 (17.9) 9 (22.5) 
1 62 (73.8) 23 (57.5) 
2 7 (8.3) 8 (20.0) 
Histology, n (%) 
Adenocarcinoma 32 (38.1) 17 (42.5) 
Squamous carcinoma 50 (59.5) 22 (55.0) 
Other 2 (2.4) 1 (2.5) 
Clinical stage, n (%) 
IIIA 40 (47.6) 17 (42.5) 
IIIB 44 (52.4) 23 (57.5) 
Table 2. Mean values of the basic hematological parameters according to age 
<!--Col Count:4--> <70 years (n = 84) ≥70 years (n = 40) p value 
Hemoglobin, g/dL 13.2 12.3 0.0158 
Neutrophils, cells/mm3 6,531 5,790 0.0622 
Lymphocytes, cells/mm3 2,126 1,919 0.001 
Platelets, cells/mm3 294,259 279,500 0.4493 
Table 3. Median values of inflammation-based indexes in the two groups depending on age 
<!--Col Count:4--> <70 years (n = 84) ≥70 years (n = 40) p value 
PNI 45.19 42.15 0.0463 
NLR 3.42 3.41 0.7043 
PLR 151.97 168.45 0.3035 
ALI 31.90 32.93 0.8018 
GPS, % 
0 25.4 4.6 
1 27.1 31.8 
2 47.5 63.6 0.107 
For the GPS, percentages of patients according to the presence of risk factors are shown. PNI, Prognostic Nutritional Index; 
NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ALI, advanced lung cancer inflammation index; 
GPS, Glasgow Prognostic Score. 
